Our analysis results revealed notably higher levels of CD93 expression among IDH wild forms, non-codeleted 1p19q subforms, and unmethylated MGMT promoter subforms in comparison to levels in gliomas of the IDH mutation subtype (Fig. 1c, d for total WHO grades; e, f for low WHO grade; g, h for high WHO grades) and the codeleted 1p19q subform (Fig. 1i, j) in combination with methylated MGMT promoter subtype (Fig. 1k, l) according to the TCGA and CGGA databases. The gene discussed is CD93; the disease is central nervous system cancer.